Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Advanced MedTech Acquires WIKKON, a Shenzhen Urology Device Maker

publication date: Sep 13, 2022

Singapore’s Advanced MedTech Holdings (AMTH) acquired a majority interest in WIKKON, a Shenzhen company that develops urology products and shock wave therapy devices for kidney stones. WIKKON focuses on urological and orthopedic conditions, erectile dysfunction and joint, muscle or tissue pain along with kidney stones. Both companies claim a major share for exterior kidney stone devices in their own markets. AMTH, a wholly owned subsidiary of Singapore’s Temasek, was spun out of Accuron Technology in 2019. It expects to acquire the rest of WIKKON by the end of 2022. The purchase price was not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital